Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag,100µg  

Recombinant Cynomolgus / Rhesus macaque CD19 (20-292) Protein, Fc Tag,100µg

Recombinant Cynomolgus / Rhesus Macaque CD19 (20-292) Protein, Pro 20 - Lys 292, produced in human 293 cells (HEK293), Fc Tag

Synonym
recombinant, protein, CD19, B4, CVID3, MGC12802

More details

CD9-C5251-100

Availability: within 7 days

533,00 €

Background
B-lymphocyte antigen CD19 (CD19) is also known as B-lymphocyte surface antigen B4, Differentiation antigen CD19 and T-cell surface antigen Leu-12, which is a single-pass type I  membrane protein and contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 forms a complex with CD21, CD81 and CD225 in the membrane of mature B cells. CD19 interacts with GRB2 and SOS when phosphorylated on Tyr-348 and/or Tyr-378. CD19 also interacts with PLCG2 when phosphorylated on Tyr-409. CD19 is an important pan B cell marker and co-stimulatory protein in humans and mice. CD19 is a hallmark differentiation antigen of the B cell lineage and positively regulates antigen receptor signal transduction in mature B cells. CD19 defines signaling thresholds for the Ag receptor as well as other cell surface receptors that regulate B lymphocyte selection, activation, and differentiation. Defects in CD19 are a cause of hypogammaglobulinemia.

Source
Recombinant Cynomolgus / Rhesus Macaque CD19 (20-292) Protein, Fc Tag (CD9-C5251) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 292 (Accession # F7F486). In the region Pro 20 - Lys 292, the AA sequence of Cynomolgus and Rhesus macaque CD19 are homologus.
Predicted N-terminus: Pro 20

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.7kDa. The protein migrates as 62-95 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.

Reconstitution
See Certificate of Analysis for reconstitution instructions and specific concentrations.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Clinical and Translational Updates

(1) "SUPERVISED AND UNSUPERVISED LEARNING TO DEFINE THE CARDIOVASCULAR RISK OF PATIENTS ACCORDING TO AN EXTRACELLULAR VESICLE MOLECULAR SIGNATURE"
Burrello, Burrello, Vacchi et al
J Hypertens (2022) 40 (Suppl 1), e138
(2) "Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity"
Zhang, Shao, Li et al
J Immunother (2022)
(3) "scRNA-seq reveals ATPIF1 activity in control of T cell antitumor activity"
Zhong, Wang, Wang et al
Oncoimmunology (2022) 11 (1), 2114740
Showing 1-3 of 14298 papers.